Respiratory medicine · 2025
Integrative therapy for lower limb venous thrombosis in patients with COPD: a trial of Rhodiola rosea polyglucoside and pulmonary rehabilitation as a synergistic combination.
СтатьяРандомизированное исследованиеПоддержка исследования: вне правительства СШАНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Ye Rui-Hai, Wang Zhen, Ren Zhe, Mao Ya-Jun, Xu Xue, Lv Xin
Аннотация
BACKGROUND: This study aimed to evaluate the synergistic effect of salidroside and pulmonary rehabilitation in patients with chronic obstructive pulmonary disease (COPD) complicated by lower extremity deep vein thrombosis (LEDVT).
METHODS: Eighty-two patients with COPD and LEDVT were randomly assigned to a control group (n = 41; low-molecular-weight heparin calcium plus pulmonary rehabilitation) or a combined group (n = 41; pulmonary rehabilitation plus salidroside). Clinical efficacy, hemorheological parameters, and serum hypoxia-inducible factor-1α (HIF-1α) and vascular endothelial growth factor (VEGF) levels were compared.
RESULTS: The total effective rate was higher in the combined group (95.12 %) than in the control group (75.61 %; P = 0.045), with no difference in adverse event incidence (17.07 % vs 9.76 %; P = 0.331). After 14 days, the combined group showed greater improvement in swelling, pain, skin temperature, and Homans's sign (all P < 0.05). Hemorheological parameters improved more significantly, including plasma viscosity (0.70 ± 0.08 vs 1.25 ± 0.30 mPa s), high-shear viscosity (4.10 ± 0.22 vs 5.00 ± 0.45 mPa s), and low-shear viscosity (7.84 ± 0.20 vs 10.93 ± 0.43 mPa s; all P < 0.001). HIF-1α levels were lower and VEGF levels higher in the combined group (both P < 0.001).
CONCLUSION: Salidroside combined with pulmonary rehabilitation significantly improved clinical outcomes, oxygenation, and endothelial repair in COPD with LEDVT, likely via modulation of the HIF-1α/VEGF pathway, without increasing adverse effects.
METHODS: Eighty-two patients with COPD and LEDVT were randomly assigned to a control group (n = 41; low-molecular-weight heparin calcium plus pulmonary rehabilitation) or a combined group (n = 41; pulmonary rehabilitation plus salidroside). Clinical efficacy, hemorheological parameters, and serum hypoxia-inducible factor-1α (HIF-1α) and vascular endothelial growth factor (VEGF) levels were compared.
RESULTS: The total effective rate was higher in the combined group (95.12 %) than in the control group (75.61 %; P = 0.045), with no difference in adverse event incidence (17.07 % vs 9.76 %; P = 0.331). After 14 days, the combined group showed greater improvement in swelling, pain, skin temperature, and Homans's sign (all P < 0.05). Hemorheological parameters improved more significantly, including plasma viscosity (0.70 ± 0.08 vs 1.25 ± 0.30 mPa s), high-shear viscosity (4.10 ± 0.22 vs 5.00 ± 0.45 mPa s), and low-shear viscosity (7.84 ± 0.20 vs 10.93 ± 0.43 mPa s; all P < 0.001). HIF-1α levels were lower and VEGF levels higher in the combined group (both P < 0.001).
CONCLUSION: Salidroside combined with pulmonary rehabilitation significantly improved clinical outcomes, oxygenation, and endothelial repair in COPD with LEDVT, likely via modulation of the HIF-1α/VEGF pathway, without increasing adverse effects.